New Drugs of 2012, Part 1

Author: Michael A. Mancano, PharmD

New Drugs of 2012, Part 1

Michael A. Mancano, PharmD
Clinical Professor of Pharmacy Practice
Chair, Department of Pharmacy Practice
Temple University School of Pharmacy
Philadelphia, Pennsylvania

Clinical Consultant, Pennsylvania Hospital
Department of Pharmacy
Philadelphia, Pennsylvania

---

Disclosures

The following contributors have no relevant financial relationships with commercial interests to disclose.

Faculty
Michael A. Mancano, PharmD

Pharmacy Times Office of Continuing Professional Education Planning Staff
Judy V. Lum, MPA, and Elena Beyzarov, PharmD

Pharmacy Times Editorial Staff
Jennifer Whartenby and David Allikas

PTOCPE uses an anonymous peer reviewer as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

---

Educational Objectives

Upon completion of this educational activity, participants should be able to:

1. Discuss the clinical indications of the new drugs approved by the FDA in 2012.
2. Explain the various mechanisms of action of the drugs discussed within this activity.
3. Identify the clinically relevant drug interactions and the most common adverse reactions for the drugs reviewed in this activity.
4. Explain the approved dosing guidelines and recommended dosage adjustments for the drugs reviewed.

Target audience: Pharmacists
Type of activity: Knowledge
Release date: February 10, 2013
Expiration date: February 10, 2015
Estimated time to complete activity: 2 hours
Fee: This lesson is free online

Click here to view this activity.